BeOne Medicines (ONC) Operating Margin (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Operating Margin of 16.51% for Q1 2026, up 1552.0% year-over-year from 1.0% in Q1 2025, and up 33.69% quarter-over-quarter from 12.35% in Q4 2025.
Powered by 
Analysis
BeOne Medicines (ONC) Operating Margin (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Operating Margin for 12 consecutive years, with 16.51% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 1552.0% year-over-year to 16.51%; the TTM figure through Mar 2026 stood at 11.95% (up 1903.0% YoY), while the FY2025 annual figure was 8.37%, up 2328.0% from the prior year.
- Operating Margin improved to 16.51% in Q1 2026 per ONC's latest filing, from 12.35% in the prior quarter.
- Across five years, Operating Margin topped out at 16.51% in Q1 2026 and bottomed at 144.57% in Q1 2022.
- Historically, Operating Margin has averaged 43.58% across 5 years, with a median of 17.15% in 2023.
- On a YoY basis, Operating Margin climbed as much as 18794 bps in 2022 and fell as far as 21235 bps in 2022.
- BeOne Medicines' Operating Margin stood at 123.29% in 2022, then surged by 51 bps to 60.5% in 2023, then surged by 88 bps to 7.04% in 2024, then surged by 275 bps to 12.35% in 2025, then soared by 34 bps to 16.51% in 2026.
- Business Quant data shows ONC's Operating Margin at 16.51% in Q1 2026, 12.35% in Q4 2025, and 11.55% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 19.75% |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | -0.36% |
| 10 | Incyte | 25.64 Bn | 21.11 Bn | 1.57 Bn | 41.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.06% |
| Mar 31, 2026 | 16.51% |
| Dec 31, 2025 | 12.35% |
| Sep 30, 2025 | 11.55% |
| Jun 30, 2025 | 6.68% |
| Mar 31, 2025 | 0.99% |
| Dec 31, 2024 | -7.04% |
| Sep 30, 2024 | -12.01% |
| Jun 30, 2024 | -11.53% |
| Mar 31, 2024 | -34.77% |
| Dec 31, 2023 | -60.50% |
| Sep 30, 2023 | -17.15% |
| Jun 30, 2023 | -53.54% |
| Mar 31, 2023 | -82.91% |
| Dec 31, 2022 | -123.29% |
| Sep 30, 2022 | -113.09% |
| Jun 30, 2022 | -128.64% |
| Mar 31, 2022 | -144.57% |
| Dec 31, 2021 | -267.19% |
| Sep 30, 2021 | -223.95% |